Biohaven (BHVN) Competitors $14.77 -0.33 (-2.19%) Closing price 08/1/2025 03:59 PM EasternExtended Trading$14.59 -0.18 (-1.25%) As of 08/1/2025 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock BHVN vs. LNTH, AXSM, TLX, PCVX, MRUS, KRYS, CYTK, ZLAB, ADMA, and ABVXShould you be buying Biohaven stock or one of its competitors? The main competitors of Biohaven include Lantheus (LNTH), Axsome Therapeutics (AXSM), Telix Pharmaceuticals (TLX), Vaxcyte (PCVX), Merus (MRUS), Krystal Biotech (KRYS), Cytokinetics (CYTK), Zai Lab (ZLAB), ADMA Biologics (ADMA), and Abivax (ABVX). These companies are all part of the "pharmaceutical products" industry. Biohaven vs. Its Competitors Lantheus Axsome Therapeutics Telix Pharmaceuticals Vaxcyte Merus Krystal Biotech Cytokinetics Zai Lab ADMA Biologics Abivax Lantheus (NASDAQ:LNTH) and Biohaven (NYSE:BHVN) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, earnings, valuation, risk, dividends, analyst recommendations, institutional ownership and media sentiment. Which has higher earnings & valuation, LNTH or BHVN? Lantheus has higher revenue and earnings than Biohaven. Biohaven is trading at a lower price-to-earnings ratio than Lantheus, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioLantheus$1.53B3.18$312.44M$3.5220.05BiohavenN/AN/A-$846.42M-$9.36-1.58 Do institutionals and insiders hold more shares of LNTH or BHVN? 99.1% of Lantheus shares are held by institutional investors. Comparatively, 88.8% of Biohaven shares are held by institutional investors. 1.5% of Lantheus shares are held by company insiders. Comparatively, 16.0% of Biohaven shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth. Is LNTH or BHVN more profitable? Lantheus has a net margin of 16.55% compared to Biohaven's net margin of 0.00%. Lantheus' return on equity of 36.99% beat Biohaven's return on equity.Company Net Margins Return on Equity Return on Assets Lantheus16.55% 36.99% 20.55% Biohaven N/A -257.07%-164.01% Does the media prefer LNTH or BHVN? In the previous week, Biohaven had 7 more articles in the media than Lantheus. MarketBeat recorded 27 mentions for Biohaven and 20 mentions for Lantheus. Lantheus' average media sentiment score of 0.91 beat Biohaven's score of 0.33 indicating that Lantheus is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Lantheus 13 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Biohaven 3 Very Positive mention(s) 1 Positive mention(s) 22 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Do analysts prefer LNTH or BHVN? Lantheus presently has a consensus target price of $131.20, suggesting a potential upside of 85.91%. Biohaven has a consensus target price of $58.46, suggesting a potential upside of 295.81%. Given Biohaven's stronger consensus rating and higher probable upside, analysts clearly believe Biohaven is more favorable than Lantheus.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Lantheus 0 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.83Biohaven 0 Sell rating(s) 1 Hold rating(s) 12 Buy rating(s) 2 Strong Buy rating(s) 3.07 Which has more volatility and risk, LNTH or BHVN? Lantheus has a beta of 0.14, meaning that its share price is 86% less volatile than the S&P 500. Comparatively, Biohaven has a beta of 0.98, meaning that its share price is 2% less volatile than the S&P 500. SummaryLantheus beats Biohaven on 9 of the 16 factors compared between the two stocks. Get Biohaven News Delivered to You Automatically Sign up to receive the latest news and ratings for BHVN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding BHVN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BHVN vs. The Competition Export to ExcelMetricBiohavenMED IndustryMedical SectorNYSE ExchangeMarket Cap$1.54B$3.00B$5.48B$20.68BDividend YieldN/A2.43%4.73%3.67%P/E Ratio-1.5817.6228.6729.07Price / SalesN/A179.18373.9066.27Price / CashN/A41.9535.4522.84Price / Book3.538.508.274.43Net Income-$846.42M-$55.06M$3.24B$994.22M7 Day Performance9.45%-3.98%-3.69%-3.35%1 Month PerformanceN/A9.59%4.33%-2.06%1 Year Performance-58.84%6.72%25.95%10.15% Biohaven Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BHVNBiohaven2.3606 of 5 stars$14.77-2.2%$58.46+295.8%-61.3%$1.54BN/A-1.58239Trending NewsUpcoming EarningsLNTHLantheus4.6193 of 5 stars$72.41-0.7%$131.20+81.2%-28.4%$5.01B$1.54B20.57700News CoverageUpcoming EarningsAnalyst RevisionAXSMAxsome Therapeutics4.8236 of 5 stars$100.39-0.4%$172.33+71.7%+19.8%$4.94B$432.16M-17.40380Positive NewsUpcoming EarningsTLXTelix PharmaceuticalsN/A$13.96-1.7%$22.33+60.0%N/A$4.72B$516.72M0.00N/AGap DownHigh Trading VolumePCVXVaxcyte2.2389 of 5 stars$35.87-2.1%$136.50+280.5%-58.0%$4.63BN/A-8.99160News CoveragePositive NewsUpcoming EarningsMRUSMerus2.9208 of 5 stars$65.59-1.8%$86.40+31.7%+25.1%$4.54B$54.73M-16.0837News CoverageKRYSKrystal Biotech4.8885 of 5 stars$152.91+3.6%$211.33+38.2%-21.0%$4.42B$333.45M36.76210Upcoming EarningsCYTKCytokinetics4.0154 of 5 stars$36.63-1.5%$70.92+93.6%-36.6%$4.37B$18.47M-6.92250News CoverageUpcoming EarningsAnalyst ForecastInsider TradeZLABZai Lab2.217 of 5 stars$38.69+4.1%$54.28+40.3%+99.7%$4.30B$418.33M-15.541,869News CoveragePositive NewsUpcoming EarningsShort Interest ↑Gap UpADMAADMA Biologics4.2926 of 5 stars$18.00-0.1%$27.67+53.7%+57.7%$4.30B$459.38M21.18530Upcoming EarningsABVXAbivax3.6107 of 5 stars$66.57+0.1%$80.00+20.2%+511.7%$4.23BN/A0.0061News CoverageAnalyst ForecastGap DownHigh Trading Volume Related Companies and Tools Related Companies Lantheus Alternatives Axsome Therapeutics Alternatives Telix Pharmaceuticals Alternatives Vaxcyte Alternatives Merus Alternatives Krystal Biotech Alternatives Cytokinetics Alternatives Zai Lab Alternatives ADMA Biologics Alternatives Abivax Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:BHVN) was last updated on 8/2/2025 by MarketBeat.com Staff From Our PartnersElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredChina just unlocked Nvidia’s AI chips—what that means for youTired of Missing Big AI Moves Like Nvidia? You’re not the problem—your trading system is. Tim’s XGPT system...Timothy Sykes | SponsoredThis Social Security Shift Could Boost Benefits by 400%If you currently collect Social Security—or plan to in the future—this may be one of the most important update...InvestorPlace | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredA new rule goes live in July — and the banks are quietly crushing itA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredYour blueprint for crypto wealthMark August 12th on your calendar. 27 of crypto's most successful minds are about to reveal everything…Crypto 101 Media | SponsoredJeff Bezos Launches "ChatGPT Killer"?Amazon just launched Nova—its secretive new AI system designed to rival ChatGPT. Bezos says he now spends 95% ...Stansberry Research | SponsoredAlien rocks potentially worth trillions…It might look like just a weird rock—but it’s tied to a discovery 60 Minutes says could be worth up to $16 tri...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Biohaven Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Biohaven With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free BHVN Stock Alerts